Use of cytokines in the treatment of acute myelocytic leukemia: A critical review

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1371-1382

  Geller, R B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; CYTOKINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; MILODISTIM; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0029978349     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1371     Document Type: Review

References (65)

1. Mayer RJ: Current chemotherapeutic treatment approaches to the management of previously untreated adults with de novo acute myelogenous leukemia. Semin Oncol 14:384-396, 1987
2. Geller RB: Post-remission therapy of acute myelocytic leukemia in adults: Curability breeds controversy. Leukemia 6:915-925, 1992
3. Kufe D, Spriggs D, Egan EM, et al: Relationships among ara-CTP pools, formation of (ara-C) DNA, and cytotoxicity of human leukemic cells. Blood 64:54-58, 1984
4. Spriggs D, Robbins G, Ohno Y, et al: Detection of 1-β-D arabinofuranosylcytosine incorporation into DNA in vivo. Cancer Res 47:6532-6536, 1987
5. Raza A, Maheshwari Y, Mandava N, et al: Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia. Semin Oncol 14:217-225, 1987
6. Spriggs DR, Robbins G, Arthur K, et al: Prolonged high dose ara-C infusions in acute leukemia. Leukemia 2:304-306, 1988
7. Hinemann V, Estey E, Keating MJ, et al: Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol 7:622-628, 1989
8. Burke PJ, Vaughan WP, Karp JE: A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. Blood 55:960-968, 1980
9. Vaughan WP, Karp JE, Burke PJ: Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64:975-980, 1984
10. Bishop JF, Matthews JP, Young GA, et al: High dose cytosine arabinoside (Ara-C) in induction prolongs remission in acute myeloid leukemia (AML): Updated results of a randomized phase III trial. Blood 84:232a, 1994 (suppl, abstr)
11. Bhalla K, Ibrado AM, Bullock G, et al: GM-CSF/IL-3 fusion protein (PIXY321) enhances high dose ara-C induced programmed cell death or apoptosis in human myeloid leukemic cells. Blood 80:2883-2895, 1992
12. Park LS, Waldron PE, Friend D, et al: Interleukin-3, GM-CSF. and G-CSF receptor expression on cell lines and primary leukemia cells: Receptor heterogeneity and relationship to growth factor responsiveness. Blood 74:56-65, 1989
13. Hiddemann W, Kiehl M, Zühisdorf M, et al: GM-CSF and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Semin Oncol 19:31-37, 1992
14. Miyauchi J, Kelleher CA, Wang C, et al: Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 73:1272-1278, 1989
15. Lista P, Porcu P, Avanzi GC, et al: Interleukin 3 enhances the cytotoxic activity of 1-β-D-arabinofuranosylcytosine (ara-C) on acute myeloblastic leukemia (AML) cells. Br J Haematol 69:121-123, 1988
16. Vellenga E, Ostapovicz D, O'Rourke B, et al: Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1:584-589, 1987
17. Brach M, Klein H, Platzer E, et al: Effect in interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts. Exp Hematol 18:748-753, 1990
18. Griffin JD, Young D, Herrmann F, et al: Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 67:1448-1453, 1986
19. Vellenga E, Young DC, Wagner K, et al: The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 69:1771-1776, 1987
20. Miyauchi J, Kelleher CA, Yang YC, et al: The effect of three recombinant growth factors, IL-3, GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 70:657-663, 1987
21. Löwenberg B, Touw IP: Hematopoietic growth factors and their receptors in acute leukemia. Blood 81:281-292, 1993
22. Sachs L, Lotem J: Control of programmed cell death in normal leukemia cells: New implication for therapy. Blood 82:15-21, 1993
23. Andreeff M, Drach J, Zhao S, et al: Cell kinetic, molecular and clinical analysis of growth factor sensitization of myeloid leukemia, in Cacciola E, Deisseroth AB, Giustolisi R (eds): Hemopoietic Growth Factors, Oncogenes and Cytokines in Clinical Hematology. Basel, Switzerland, Karger, 1994, pp 112-136
24. Estey EH, Dixon D, Kantarjian HM, et al: Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 75:1766-1769, 1990
25. Baer MR, Christiansen NP, Frankel FS, et al: High-dose cytarabine, idarubicin and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia. Semin Oncol 20:6-12, 1993 (suppl 8)
26. Geller RB, Morris L, Winton EF, et al: Intensive time sequential induction therapy with VP-16, mitoxantrone and ara-C for patients (pts) with newly diagnosed acute myelogenous leukemia (AML) or refractory/relapsed acute leukemia: A potential role for GM-CSF to enhance recruitment. Blood 84:144a, 1994 (suppl, abstr)
27. Büchner T, Hiddemann W, Wormann, et al: GM-CSF multiple course priming and long-term administration in newly diagnosed AML. Hematologic and therapeutic effects. Blood 84:27a, 1994 (suppl, abstr)
28. Bettelheim P, Valent P, Andreeff M, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 77:700-711, 1991
29. Archimbaud E, Fenaux P, Reiffers J, et al: Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 7:372-377, 1993
30. Cannistra SA, DiCarlo J, Groshek P, et al: Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 5:230-238, 1991
31. Estey E, Thall P, Andreeff M, et al: Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12:671-678, 1994
32. Ohno R, Naoe T, Kanamaru A, et al: A double-blind controlled study of granulocyte colony-stimulating factor started 2 days before induction chemotherapy in refractory acute myeloid leukemia. Blood 83:2086-2092, 1994
33. Cortes J, Andreeff M, O'Brien S, et al: Use of interleukin-3 (IL-3) for sensitization to chemotherapy in relapsed or refractory acute myeloid leukemia (AML). Blood 84:232a, 1994 (suppl, abstr)
34. Gore SD, Weng LJ, Burke PJ: Biologic and clinical impact of growth factor (GF) augmentation of post-remission chemotherapy for acute myeloid leukemia. Blood 84:582a, 1994 (suppl, abstr)
35. Feldman E, Geller RB, Soiter K: PIXY321 in combination with high dose cytarabine and mitoxantrone in poor prognosis acute myeloid leukemia (AML). Blood 86:520a, 1995 (suppl, abstr)
36. Geller RB: Clinical use of myeloid growth factors in the treatment of acute myelocytic leukemia. Oncology 7:49-53, 1993 (suppl)
37. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871-877, 1990
38. Büchner T, Hiddemann W, Koenigsmann M. et al: Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190-1197, 1991
39. Büchner T, Hiddemann W, Wörmann B, et al: The role of GM-CSF in the treatment of acute myeloid leukemia. Leuk Lymphoma 11:2:21-24, 1993
40. Estey EH. Use of colony-stimulating factors in the treatment of acute myeloid leukemia. Blood 83:2015-2019, 1994
41. Rowe JM, Andersen JW, Mazza JJ, et al: A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-462, 1995
42. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1671-1677, 1995
43. Witz F, Harousseau JL, Cahn JY, et al: GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML). Blood 84:231a, 1994 (suppl, abstr)
44. Zittoun R, Mandelli F, de Witte T, et al: Recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) during induction treatment of acute myelogenous leukemia (AML). A randomized trial from EORTC-GIMEMA leukemia cooperative groups. Blood 84:231a, 1994 (suppl, abstr)
45. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678-1683, 1995
46. Dorr RT: Clinical properties of yeast-derived verses E coli-derived granulocyte-macrophage colony-stimulating factor. Clin Therapeut 15:I-XI, 1993
47. Rowe JM, Rubin A, Mazza JJ, et al: Incidence of infections in adult patients (> 55 years) with acute myeloid leukemia treated with yeast-derived GM-CSF (Sargamostin): Results of a double-blind prospective study by the Eastern Cooperative Oncology Group. Leuk Lymphoma (in press)
48. Ralph PW. Biological properties and molecular biology of the human macrophage growth factor; CSF-1. Immunobiology 172:194-204, 1986
49. Karbassi A, Becker JM, Foster JS, et al: Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: Evidence for augmented expression of mannose receptors. J Immunol 139:417-421, 1987
50. Nemunaitis J, Meyers JD, Buckner CD, et al: Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 78:907-913, 1991
51. Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773-1778, 1991
52. Gorin NC, Coiffier B, Hayat M, et al: rhu GM-CSF shortens aplasia duration after ABMT in non-Hodgkin's lymphoma: A randomized placebo-controlled double-blind study. Bone Marrow Transplant 7:82, 1991 (suppl 2)
53. Visani G, Gamberi B, Greenberg P, et al: The use of GM-CSF as an adjunct to autologous/syngeneic bone marrow transplantation: A prospective randomized controlled trial. Bone Marrow Transplant 7:81, 1991 (suppl 2)
54. Advani R, Chao NJ, Horning SJ, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hematopoietic stem cell transplantation for lymphoma. Ann Intern Med 116:183-189, 1992
55. Sheridan WP, Morstyn G, Wolf M, et al: Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 2:891-895, 1989
56. Taylor KM, Jagannath S, Spitzer G, et al: Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 7:1791-1799, 1989
57. Stone RM, Mayer RJ: The approach to the elderly patient with acute myeloid leukemia. Hematol Oncol Clin North Am 7:65-79, 1993
58. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
59. Gulati S, Bennett C: Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann Intern Med 116:177-182, 1992
60. Luce BR, Singer JW, Weschler JM, et al: Recombinant human granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. Pharmacoeconomics 6:42-48, 1994
61. Geller RB, Tarantolo S, Powell BL: Phase II study of pIXY321 in elderly patients (pts) with newly diagnosed acute myelocytic leukemia (AML). Blood 86:760a, 1995 (suppl, abstr)
62. Williams DE, Park LS: Hematopoietic effects of a granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein. Cancer 67:2705-2707, 1991
63. Runowicz CD, Mandeli J, Speyer J, et al: Phase I/II study of pIXY321 after cyclophosphamide and carboplatin in the treatment of patients with advanced stage ovarian cancer. Blood 80:341a, 1992 (suppl, abstr)
64. Vadhan-Raj S, Broxmeyer H, Bandres J, et al: In vivo biologic effects of pIXY321 (GM-CSF/IL-3 fusion protein) in patients with sarcoma. Blood 80:340a, 1992 (suppl, abstr)
65. Vose JM, Anderson J, Bierman PJ, et al: Initial trial of pIXY321 (GM-CSF/IL-3 fusion protein) following high-dose chemotherapy and autologous bone marrow transplantation (ABMT) for lymphoid malignancy. Proc Am Soc Clin Oncol 12:366, 1993 (abstr 1237)